Clinical Trial Update: RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia [Phase 4]

View source ↗

Summary

The Phase 4 RAPID-2 trial evaluating alternate dosing of PROCRIT (epoetin alfa) to maintain hemoglobin in chemotherapy-induced anemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Chemotherapy-induced Anemia

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Ortho Biotech Products, L.P. | Conditions: Chemotherapy, Cancer | Phase 4 | Status: TERMINATED